Sulphonamides: Deserving class as MMP inhibitors?

European Journal of Medicinal Chemistry

Volumn 60, Issue , 2013, Pages 89-100

  Jain, Pranjali ^a   Saravanan, Chinnadurai ^a   Singh, Sushil Kumar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Cancer; CGS 27023A; MMP; MMPI; Structure activity relationship; Sulphonamides

Indexed keywords

2 (N BENZYL 4 METHOXYBENZENESULFONAMIDO) N HYDROXY 3 METHYLBUTANAMIDE; 2 [N (4 METHOXYSULFONYL)(3 PYRIDINYLMETHYL)AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; BATIMASTAT; COLLAGENASE 3; CP 471 474; GELATINASE A; GELATINASE B; GLYCINE DERIVATIVE; HYDROXAMIC ACID; ILOMASTAT; KB R 7785; KBR 7785; LACTAM DERIVATIVE; MARIMASTAT; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; N1 (1 CARBAMOYL 2,2 DIMETHYLPROPYL) 2 [3 (4 CHLOROPHENYL)PROPYL] N4 HYDROXYBUTANEDIAMIDE; PD 166793; PG 116800; PRINOMASTAT; S 3304; SULFONAMIDE; THIOMORPHOLINE; UNCLASSIFIED DRUG; ZINC ION;

ALZHEIMER DISEASE; ASTHMA; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CROHN DISEASE; DERMATITIS; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; GINGIVITIS; HYDROGEN BOND; LEWIS CARCINOMA; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; OSTEOARTHRITIS; PERIODONTITIS; PSORIASIS; REVIEW; SKIN ULCER; STRUCTURE ACTIVITY RELATION; ULCERATIVE COLITIS;

EID: 84871672754     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.10.016     Document Type: Short Survey

References (91)

1. K.C. Majumdar, and S. Mondal Recent developments in the synthesis of fused sultams Chem. Rev. 111 2011 7749 7773
2. A. Scozzafava, L. Menabuoni, F. Mincione, F. Briganti, G. Mincione, and C.T. Supuran Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J. Med. Chem. 42 1999 2641 2650
3. S. Caddick, J.D. Wilden, and D.B. Judd Direct synthesis of sulfonamides and activated sulfonate esters from sulfonic acids J. Am. Chem. Soc. 126 2004 1024 1025
4. C.H. Zhou, L.L. Gan, Y.Y. Zhang, F.F. Zhang, G.Z. Wang, L. Jin, and R.X. Geng Review on supermolecules as chemical drugs Sci. China Chem. 52 2009 415 458
5. P.A. Boriack-Sjodin, S. Zeitlin, H.H. Chen, L. Crenshaw, S. Gross, A. Dantanarayana, P. Delgado, J.A. May, T. Dean, and D.W. Christianson Structural analysis of inhibitor binding to human carbonic anhydrase II Protein Sci. 7 1998 2483 2489
6. D.A. Abou El Ella, M.M. Ghorab, H.I. Heiba, and A.M. Soliman Synthesis of some new thiazolopyrane and thiazolopyranopyrimidine derivatives bearing a sulphonamide moiety for evaluation as anticancer and radiosensitizing agents Med. Chem. Res. 21 2012 2395 2407
7. C. Saravanan, and S.K. Singh Status of research on MMPs in India Expert Opin. Ther. Targets 15 2011 715 728
8. M. Pavlaki, and S. Zucker Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials Cancer Metastasis Rev. 22 2003 177 203
9. X.C. Cheng, Q. Wang, H. Fang, and W.F. Xu Role of sulfonamide group in matrix metalloproteinase inhibitors Curr. Med. Chem. 15 2008 368 373
10. J.W. Skiles, N.C. Gonnella, and A.Y. Jeng The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors Curr. Med. Chem. 11 2004 2911 2977
11. L.J. MacPherson, E.K. Bayburt, M.P. Capparelli, B.J. Carroll, R. Goldstein, M.R. Justice, L. Zhu, S.I. Hu, R.A. Melton, L. Fryer, R.L. Goldberg, J.R. Doughty, S. Spirito, V. Blancuzzi, D. Wilson, E.M. O'Byrne, V. Ganu, and D.T. Parker Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits J. Med. Chem. 40 1997 2525 2532
12. A. Scozzafava, and C.T. Supuran Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes J. Med. Chem. 43 2000 3677 3687
13. P.E. J.Hu, Q.X. Van den Steen, and G. Opdenakker Sang Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases Nat. Rev. Drug Discov. 6 2007 480 498
14. 11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents Nucl. Med. Biol. 29 2002 761 770
15. S.L. Bender, C.A. Broka, J.A. Campbell, A.L. Castelhano, L.E. Fisher, R.T. Hendricks, K. Sarma, Matrix metalloprotease inhibitors, US5932595, 1999.
16. 18F]fluoroethoxy) phenylsulphonamido)-N-hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis Appl. Radiat. Isot. 69 2011 862 868
17. J. Schröder, H. Wenzel, and H. Tschesche 3D structure and drug design J.M. Foidart, R.J. Muschel, Proteases and Their Inhibitors in Cancer Metastasis 2002 Kluwer Academic Publishers Dordrecht 127 150
18. R. Hoekstra, F.A. Eskens, and J. Verweij Matrix metalloproteinase inhibitors: current developments and future perspectives Oncologist 6 2001 415 427
19. O. Santos, C.D. McDermott, R.G. Daniels, and K. Appelt Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases Clin. Exp. Metastasis 15 1997 499 508
20. A. Price, Q. Shi, D. Morris, M.E. Wilcox, P.M. Brasher, N.B. Rewcastle, D. Shalinsky, H. Zou, K. Appelt, R.N. Johnston, V.W. Yong, D. Edwards, and P. Forsyth Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340 Clin. Cancer Res. 5 1999 845 854
21. 1′cavity Biochimie 92 2010 1501 1508
22. D. Bissett, K.J. O'Byrne, J. von Pawel, U. Gatzemeier, A. Price, M. Nicolson, R. Mercier, E. Mazabel, C. Penning, M.H. Zhang, M.A. Collier, and F.A. Shepherd Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer J. Clin. Oncol. 23 2005 842 849
23. M.P. Hudson, P.W. Armstrong, W. Ruzyllo, J. Brum, L. Cusmano, P. Krzeski, R. Lyon, M. Quinones, P. Theroux, D. Sydlowski, H.E. Kim, M.J. Garcia, W.A. Jaber, and W.D. Weaver Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (prevention of myocardial infraction early remodeling) trial J. Am. Coll. Cardiol. 48 2006 15 20
24. W.M. Yarbrough, R. Mukherjee, G.P. Escobar, J.T. Mingoia, J.A. Sample, J.W. Hendrick, K.B. Dowdy, J.E. McLean, A.S. Lowry, T.P. O'Neill, and F.G. Spinale Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling Circulation 108 2003 1753 1759
25. N. Kaludercic, M.L. Lindsey, B. Tavazzi, G. Lazzarin, and N. Paolocc Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond Cardiovasc. Ther. 26 2008 24 37
26. R.E. Chapman, A.A. Scott, A.M. Deschamps, A.S. Lowry, R.E. Stroud, J.S. Ikonomidis, and F.G. Spinale Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition J. Mol. Cell. Cardiol. 35 2003 539 548
27. A.L. Chancey, G.L. Brower, J.T. Peterson, and J.S. Janicki Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload Circulation 105 2002 1983 1988
28. M.M. Sung, C.G. Schulz, W. Wang, G. Sawicki, N.L. Bautista-López, and R. Schulz Matrix metalloproteinase-2 degrades the cytoskeletal protein α-actinin in peroxynitrite mediated myocardial injury J. Mol. Cell. Cardiol. 43 2007 429 436
29. O. Mendes, H.T. Kim, and G. Stoica Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model Clin. Exp. Metastasis 22 2005 237 246
30. M. Selman, J. Cisneros-Lira, M. Gaxiola, R. Ramirez, E.M. Kudlacz, P.G. Mitchell, and A. Pardo Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea pigs Chest 123 2003 1633 1641
31. L. Fang, X.M. Gao, X.L. Moore, H. Kiriazis, Y. Su, Z. Ming, Y.L. Lim, A.M. Dart, and X.J. Du Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction J. Mol. Cell. Cardiol. 43 2007 535 544
32. L.E. Rohde, A. Ducharme, L.H. Arroyo, M. Aikawa, G.H. Sukhova, A. Lopez-Anaya, K.F. McClure, P.G. Mitchell, P. Libby, and R.T. Lee Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice Circulation 99 1999 3063 3070
33. M.L. Lindsey, J. Gannon, M. Aikawa, F.J. Schoen, E. Rabkin, L. Lopresti-Morrow, J. Crawford, S. Black, P. Libby, P.G. Mitchell, and R.T. Lee Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction Circulation 105 2002 753 758
34. S. van Marle, A. van Vliet, F. Sollie, Y. Kambayashi, and T. Yamada-Sawada Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers Int. J. Clin. Pharmacol. Ther. 43 2005 282 293
35. T.G. Mant, D. Bradford, D.M. Amin, J. Pisupati, Y. Kambayashi, Y. Yano, K. Tanaka, and T. Yamada-Sawada Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers Br. J. Clin. Pharmacol. 63 2007 512 526
36. G. Dormán, K. Kocsis-Szommer, C. Spadoni, and P. Ferdinandy MMP inhibitors in cardiac diseases: an update Recent Pat. Cardiovasc. Drug Discov. 2 2007 186 194
37. T.S. Rush III, and R. Powers The application of X-ray, NMR, and molecular modeling in the design of MMP inhibitors Curr. Top. Med. Chem. 4 2004 1311 1327
38. I. Bertini, V. Calderone, M. Fragai, A. Giachetti, M. Loconte, C. Luchinat, M. Maletta, C. Nativi, and K.J. Yeo Exploring the subtleties of drug- receptor interactions: the case of matrix metalloproteinases J. Am. Chem. Soc. 129 2007 2466 2475
39. E. Attolino, V. Calderone, E. Dragoni, M. Fragai, B. Richichi, C. Luchinat, and C. Nativi Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs) Eur. J. Med. Chem. 45 2010 5919 5925
40. M. Ilies, M.D. Banciu, and A. Scozzafava Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating arylsulfonylureido and 5-dibenzo-suberenyl/suberyl moieties Bioorg. Med. Chem. 11 2003 2227 2239
41. C.T. Supuran, A. Scozzafava, and A. Mastrolorenzo Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics Exp. Opin. Ther. Pat. 11 2001 221 259
42. B. Pirard Insight into the structural determinants for selective inhibition of matrix metalloproteinases Drug Discov. Today 12 2007 640 646
43. J.Y. Winum, A. Scozzafava, J.L. Montero, and C.T. Supuran Therapeutic potential of sulfamides as enzyme inhibitors Med. Res. Rev. 26 2006 767 792
44. C.T. Supuran, A. Casini, and A. Scozzafava Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents Med. Res. Rev. 23 2003 535 538
45. E. Gavuzzo, G. Pochetti, F. Mazza, C. Gallina, B. Gorini, S. D'Alessio, M. Pieper, H. Tschesche, and P.A. Tucker Two crystal structures of human neutrophil collagenase, one complexed with a primed- and the other with an unprimed-side inhibitor: implications for drug design J. Med. Chem. 43 2000 3377 3385
46. P.M. O'Brien, D.F. Ortwine, A.G. Pavlovsky, J.A. Picard, D.R. Sliskovic, B.D. Roth, R.D. Dyer, L.L. Jhonson, C.F. Man, and H. Hallak Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors J. Med. Chem. 43 2000 156 166
47. A. Rossello, E. Nuti, P. Carelli, E. Orlandini, M. Macchia, S. Nencetti, M. Zandomeneghi, F. Balzano, G.U. Barretta, A. Albini, R. Benelli, G. Cercignani, G. Murphy, and A. Balsamo N-i-Propoxy-N- biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP Bioorg. Med. Chem. Lett. 15 2005 1321 1326
48. J.J.-W. Duan, L. Chen, Z.R. Wasserman, Z. Lu, R.Q. Liu, M.B. Covington, M. Qian, K.D. Hardman, R.L. Magolda, R.C. Newton, D.D. Christ, R.R. Wexler, and C.P. Decicco Discovery of γ-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor α converting enzyme: design, synthesis, and structure-activity relationships J. Med. Chem. 45 2002 4954 4957
49. A. Rossello, E. Nuti, E. Orlandini, P. Carelli, S. Rapposelli, M. Macchia, F. Minutolo, L. Carbonaro, A. Albini, R. Benelli, G. Cercignani, G. Murphy, and A. Balsamo New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) Bioorg. Med. Chem. Lett. 12 2004 2441 2450
50. E. Nuti, F. Casalini, S.I. Avramova, S. Santamaria, G. Cercignani, L. Marinelli, V.L. Pietra, E. Novellino, E. Orlandini, S. Nencetti, T. Tuccinardi, A. Martinelli, N.H. Lim, R. Visse, H. Nagase, and A. Rossello N-O-Isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis J. Med. Chem. 52 2009 4757 4773
51. J. Li, T.S. Rush III, W. Li, D. DeVincentis, X. Du, Y. Hu, J.R. Thomason, J.S. Xiang, J.S. Skotnicki, S. Tam, K.M. Cunningham, P.S. Chockalingam, E.A. Morris, and J.I. Levin Synthesis and SAR of highly selective MMP-13 inhibitors Bioorg. Med. Chem. Lett. 15 2005 4961 4966
52. Y. Hu, J.S. Xiang, M.J. DiGrandi, X. Du, M. Ipek, L.M. Laakso, J. Li, W. Li, T.S. Rush, J. Schmid, J.S. Skotnicki, S. Tam, J.R. Thomason, Q. Wang, and J.I. Levin Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis Bioorg. Med. Chem. Lett. 13 2005 6629 6644
53. L.A. Reiter, R.P. Robinson, K.F. McClure, C.S. Jones, M.R. Reese, P.G. Mitchell, I.G. Otterness, M.L. Bliven, J. Liras, S.R. Cortina, K.M. Donahue, J.D. Eskra, R.J. Griffths, M.E. Lame, A. Lopez-Anaya, G.J. Martinelli, S.M. McGahee, S.A. Yocum, L.L. Lopresti-Morrow, L.M. Tobiassen, and M.L. Vaughn-Bowser Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1 Bioorg. Med. Chem. Lett. 14 2004 3389 3395
54. S.M. Yang, R.H. Scannevin, B. Wang, S.L. Burke, L.J. Wilson, P. Karnachi, K.J. Rhodes, B. Lagu, and W.V. Murray β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 1 design, synthesis, and lead identification Bioorg. Med. Chem. Lett. 18 2008 1135 1139
55. W. Li, J. Li, Y. Wu, J. Wu, R. Hotchandani, K. Cunningham, I. McFadyen, J. Bard, P. Morgan, F. Schlerman, X. Xu, S. Tam, S.J. Goldman, C. Williams, J. Sypek, and T.S. Mansour Selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3- methylbutanoic acid (MMP408) J. Med. Chem. 52 2009 1799 1802
56. W. Li, J. Li, Y. Wu, F. Rancati, S. Vallese, L. Raveglia, J. Wu, R. Hotchandani, N. Fuller, K. Cunningham, P. Morgan, S. Fish, R. Krykbaev, X. Xu, S. Tam, S.J. Goldman, W. Abraham, C. Williams, J. Sypek, and T.S. Mansour Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma J. Med. Chem. 52 2009 5408 5419
57. C.A. Kontogiorgis, P. Papaioannou, and D.J. Hadjipavlou-Litina Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results Curr. Med. Chem. 12 2005 339 355
58. R. Oltenfreiter, L. Staelens, V. Kersemans, B. Cornelissen, F. Frankenne, J.M. Foidart, C. Van de Wiele, and G. Slegers Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents Appl. Radiat. Isot. 64 2006 677 685
59. O. Nicolotti, T.F. Miscioscia, F. Leonetti, G. Muncipinto, and A. Carotti Screening of matrix metalloproteinases available from the protein data bank: insights into biological functions, domain organization, and zinc binding groups J. Chem. Inf. Model. 47 2007 2439 2448
60. S.M. Marques, E. Nuti, A. Rossello, C.T. Supuran, T. Tuccinardi, A. Martinelli, and M.A. Santos Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates J. Med. Chem. 51 2008 7968 7979
61. J.I. Levin, Y. Gu, F.C. Nelson, A. Zask, J.F. DiJoseph, M.A. Sharr, A. Sung, G. Jin, R. Cowling, P. Chanda, S. Cosmi, C.L. Hsiao, W. Edris, J. Wilhelm, L.M. Killar, and J.S. Skotnicki Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases Bioorg. Med. Chem. Lett. 11 2001 239 242
62. T.E. Barta, D.P. Becker, L.J. Bedell, G.A. De Crescenzo, J.J. McDonald, G.E. Munie, S. Rao, H.S. Shieh, R. Stegeman, A.M. Stevens, and C.I. Villamil Synthesis and activity of selective MMP inhibitors with an aryl backbone Bioorg. Med. Chem. Lett. 10 2000 2815 2817
63. D. Ma, W. Wu, G. Yang, J. Li, J. Li, and Q. Ye Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors Bioorg. Med. Chem. Lett. 14 2004 47 50
64. R.A. Pauwels, and K.F. Rabe Burden and clinical features of chronic obstructive pulmonary disease (COPD) Lancet 364 2004 613 620
65. D. Dou, G. He, K.R. Alliston, and W.C. Groutas Dual function inhibitors of relevance to chronic obstructive pulmonary disease Bioorg. Med. Chem. Lett. 21 2011 3177 3180
66. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, and M. Decramer A 4-year trial of tiotropium in chronic obstructive pulmonary disease N. Engl. J. Med. 359 2008 1543 1554
67. M.G. Belvisi, and K.M. Bottomley The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm. Res. 52 2003 95 100
68. S. Chakrabarti, and K.D. Patel Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology Exp. Lung Res. 31 2005 599 621
69. W. Piotrowski, P. Gorski, T. Pietras, W. Fendler, and J. Szemraj The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis Med. Sci. Monit. 17 2011 CR598 CR607
70. V. Lagente, C.L. Quement, and E. Boichot Macrophage metalloelastase (MMP-12) as a target for inflammatory respiratory diseases Expert Opin. Ther. Targets 13 2009 287 295
71. A. Scozzafava, T. Owa, A. Mastrolorenzo, and C.T. Supuran Anticancer and antiviral sulfonamides Curr. Med. Chem. 10 2003 925 953
72. Y. Wu, J. Li, J. Wu, P. Morgan, X. Xu, F. Rancati, S. Vallese, L. Raveglia, R. Hotchandani, N. Fuller, J. Bard, K. Cunninghama, S. Fish, R. Krykbaev, S. Tama, S.J. Goldman, C. Williams, T.S. Mansour, E. Saiah, J. Sypek, and W. Li Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD) Bioorg. Med. Chem. Lett. 22 2012 138 143
73. P. Norman Selective MMP-12 inhibitors: WO-2008057254 Expert Opin. Ther. Pat. 19 2009 1029 1034
74. M.J. Fray, R.P. Dickinson, J.P. Huggins, and N.L. Occleston A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers J. Med. Chem. 46 2003 3514 3525
75. G.A. Whitlock, K.N. Dack, R.P. Dickinson, and M.L. Lewis A novel series of highly selective inhibitors of MMP-3 Bioorg. Med. Chem. Lett. 17 2007 6750 6753
76. G.H. Skrepnek, and S.V. Skrepnek Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma Am. J. Manag. Care 10 2004 S129 S138
77. Chronic diseases and health promotion: WHO. Available from: www.who.int/entity/chp/topics/rheumatic/en/ (Last visited 26.09.12).
78. A.H. Riethera, S.J. Taylor, S. Liang, D.A. Gao, Z. Xiong, E.M. August, B.K. Collins, B.T. Farmer II, K. Havertya, M. Hill-Drzewi, H.D. Junker, S.M. Margarit, N. Moss, T. Neumann, J.R. Proudfoot, L.S. Keenan, R. Sekul, Q. Zhang, J. Li, and N.A. Farrow Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors Bioorg. Med. Chem. Lett. 19 2009 5321 5324
79. M.E. Schnute, and P.M. O'Brien Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis Bioorg. Med. Chem. Lett. 20 2010 576 580
80. L.A. Neuhold, L. Killar, W. Zhao, M.A. Sung, L. Warner, J. Kulik, J. Turner, W. Wu, C. Billinghurst, T. Meijers, A.R. Poole, P. Babij, and L.J. DeGennaro Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice J. Clin. Invest. 107 2001 35 44
81. J.I. Levin, J.M. Chen, M.T. Du, F.C. Nelson, T. Wehr, J.F. DiJoseph, L.M. Killar, S. Skala, A. Sung, M.A. Sharr, C.E. Roth, G. Jin, R. Cowling, L. Di, M. Sherman, Z.B. Xu, C.J. March, K.M. Mohler, R.A. Black, and J.S. Skotnicki The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines Bioorg. Med. Chem. Lett. 11 2001 2975 2978
82. A.A. Chiappori, S.G. Eckhardt, R. Bukowski, D.M. Sullivan, M. Ikeda, Y. Yano, T. Yamada-Sawada, Y. Kambayashi, K. Tanaka, M.M. Javle, T. Mekhail, C.L. O'Bryant, and P.J. Creaven A phase I pharmacokinetic and pharmacodynamic study of S-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors Clin. Cancer Res. 13 2007 2091 2099
83. M. Zafarullah, R. Ahmad, M.E. Mabrouk, A. Liacini, and H.Y. Qureshi Inhibition of matrix metalloproteinases as a feasible therapeutic target in rheumatoid arthritis Curr. Rheumatol. Rev. 4 2008 288 297
84. I.G. Rathish, K. Javed, S. Ahmad, S. Bano, M.S. Alama, M. Akhter, K.K. Pillai, S. Ovais, and M. Samim Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones Eur. J. Med. Chem. 49 2012 304 309
85. R.D. Bonfil, R. Fridman, S. Mobashery, and M.L. Cher Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis? Curr. Oncol. 15 2008 188 192
86. C.M. Overall, and O. Kleifeld Towards third generation matrix metalloproteinase inhibitors for cancer therapy Br. J. Cancer 94 2006 941 946
87. M.T. Rubino, M. Agamennone, C. Campestre, P. Campiglia, V. Cremasco, R. Faccio, A. Laghezza, F. Loiodice, D. Maggi, E. Panza, A. Rossello, and P. Tortorella Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption ChemMedChem 6 2011 1258 1268
88. V.S. Golubkov, A.V. Chernov, and A.Y. Strongin Intradomain cleavage of inhibitory prodomain is essential to protumorigenic function of membrane type-1 matrix metalloproteinase (MT1-MMP) in vivo J. Biol. Chem. 286 2011 34215 34223
89. H. Luukkaa, P. Klemi, P. Hirsimäki, T. Vahlberg, A. Kivisaari, V.M. Kähäri, and R. Grenman Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer Acta Otolaryngol. 128 2008 482 490
90. D.P. Becker, T.E. Barta, L.J. Bedell, T.L. Boehm, B.R. Bond, J. Carroll, C.P. Carron, G.A. DeCrescenzo, A.M. Easton, J.N. Freskos, C.L. Funckes-Shippy, M. Heron, S. Hockerman, C.P. Howard, J.R. Kiefer, M.H. Li, K.J. Mathis, J.J. Mcdonald, P.P. Mehta, G.E. Munie, T. Sunyer, C.A. Swearingen, C.I. Villamil, D. Welsch, J.M. Williams, Y. Yu, and J. Yao Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease J. Med. Chem. 53 2010 6653 6680
91. X. Fei, Q.H. Zheng, X. Liu, J.Q. Wang, H.B. Sun, B.H. Mock, K.L. Stone, K.D. Miller, G.W. Sledge, and G.D. Hutchins Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents Bioorg. Med. Chem. Lett. 13 2003 2217 2222